Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126665) titled 'A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
Condition:
Advanced Malignant Solid Tumor
Intervention:
Drug: MHB088C for Injection
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 2025
Target Sample Size: 116
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07126665
Published ...